Click here to load reader

Acute Lymphocytic Leukemia TABLE

  • View
    215

  • Download
    0

Embed Size (px)

Text of Acute Lymphocytic Leukemia TABLE

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    1/15

    !"#$% '()*+,"($-" '%#.%)-/ 0!''1 !"#$% 2(%3,4%5,#6 '%#.%)-/ 0!2'1

    !"#$ &"''"( )*+,*'-. -( &/-)01*( 05%78,95 $, :; (%/961

    21*3+).$*0 41")-5*1.$-"( 6 .&&+'+).$-"( "5 '()*+,83/6$6/5"($,*%5-/9 7.))"1 .(0 5.$-3+*9 !5%)-/DB)**0-(39 B+9,)8,"($,*%5-/ C O(5*&$-"(# .(0 5*L*19 F%#$9,*%5-/

    >().13*'*($ "5 )-L*1 .(0 #4)**( P c%*/$,6*3%5,)%4/3(>().13*'*($ "5 )D'4/ ("0*#P '()*+/C%5,*/$+(

    I,5% */-5P >Q4.(#-"( "5 B! #4.&* .(0 -(5-)$1.$-"( "5 4*1-"#$*+' .(0 I3%%C-54 4#)6

    Bone marrow : acute leukemia

    22Winter 13 AJalan

    ManyAuer rods

    AML M3 (Acute promyelocytic leukemia)

    Promyelocyteswith granules

    40Winter 13 AJalan

    PPSC

    MyeloidStem cell

    CFU GEMM

    MonoblastAcute monocytic

    AML M5

    Meyloblast AML M1,M2 & M3

    Eosinophil

    Erythroblast

    Megakaryoblast

    Acute ErythroleukemiaAML M6

    Acute Megakaryocyticleukemia AML M7

    Acute myelomonocyticAML M4

    AML M0

    CFU-GM

    36Winter 13 AJalan

    MeyloblastMonoblast

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    2/15

    J''ZE'' J+9,5-" 2(%3,4%5,#6 '%#.%)-/

    M&&+1# -( -(0-L-0+.)# !"# %&'(),X /4%B+%6% "%336 *9,3-X%9/$% /5C /""#)#3/$% -5 I2 /5C >I

    2/3-45/5$ "%336 d9%6%)83%e )/$#9% 3()*+,"($%6 L-824&(M) )%+/(31&E B9/56X,9)/$-,5 ,X J'' $, B-::=)& N'(*& 7 8&,,

    N%10231'= 0K'IJ'1Q4"#+1* $" -3+-.-+* ('/-'4-3+

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    3/15

    !C#3$ BGJ%33 '%#.%)-/ c/-9( J%33 '%#.%)-/ 2(%3,C(6*3/6$-" E(5C9,)%6

    !.)-3(.($ B "%33 TABI 8&,,W 3%#.%)-/=

    R.+#* GD K+'.( = &*)) )*+,*'-. L-1+# $D4* O T;?N[JKW

    !"#$ &"''"( -(\'0'+ '+/ A'(-%'-9 ?D'4/"G).#$# #*&1*$*

    ,6$%,"3/6$ /"$-?/$-54 X/"$,9C :##"&-.$*0 H-$/

    2%0&(8',8&1-'

    ^IJ [email protected]/3-45/5$ 3()*+,-C "%336 7-$+

    ;%0&(,3

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    4/15

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    5/15

    I#9.-$$V6 3()*+,)/

    P,33-"#3/9 3()*+,)/

    2,6$ ",)),53()*+,)/ -5 "+-3C9%5=

    ! +-4+G49/C%3()*+,)/ ,X I "%336=

    U "3-5-"/3 X,9)[email protected]

    !X9-"/5 0%5C%)-"1 I '@S5?,3?%)%5$ ,X )/5C-83% ,9 )/f-33/

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    6/15

    K-XX#6% 3/94% I "%33 3()*+,)/ 0K'IJ'1 2/94-5/3 W,5% 3()*+,)/

    ! +-4+ 49/C%D/449%66-?% 8#$ *,$%5$-/33( "#9/83% IG"%33 3()*+,)/=

    I "%336 49,7 C-XX#6%3( -5 6+%%$6

    J3-5-"/3 */$+,3,4(@

    >/$-%5$6 #6#/33( *9%6%5$ 7-$+ / 9/*-C3( %53/94-54 )/66 /$%-$+%9 / 6-543%

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    7/15

    !C#3$ B "%33 3%#.%)-/Z3()*+,)/< 2(",6-6 X#54,-C%6 ZE%W/9( 6(5C9,)%

    !B''@ . '.)-3(.($ = &*)) 0-#"10*1 ERaX = &*))#F

    a+* $" cB'kG: -5X%"$-,5

    V"+(0 -( m/*/5 /5C J/9-88%/5

    J3-5-"/3 6()*$,)[email protected],-( )*#-"(#C /D4*1&.)&*'-.C *().13*0 )D'4/("0*#C )-L*1 .(0 #4)**(T

    !-&1"9 /D4*1)"G.$*0 )D'4/"&D$*# -( 7B

    n#%6$-,[email protected]/-&/ $D4* "5 )D'4/"'[email protected])*+,*'-. "&&+1# -( K=?gZA -(5*&$*0 4*"4)*h

    !567%[email protected]$-*($# -(5*&$*0 H-$/ K=?gZA E.( "(&"3*(-& L-1+#F 41*#*($ H-$/ .0+)$ = &*))

    )*+,*'[email protected])D'4/"'.C . $+'"1 "5 RaX = &*))#T

    ',7 49/C% B "%33 3()*+,)/ ,X $+% 6.-5

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    8/15

    2#3$-*3% 2(%3,)/ 0*3/6)/ "%33 )(%3,)/1

    ! $#),9 ,X *3/6)/ "%336 "+9= 8( >9,3-X%9/$-,5 ,X0,')1' 8&,,) -5 $+% 8,5% )/99,7 /5C -(L")L*'*($,X )@&,&43+ /$ )#3$-*3% 6-$%6 9%6#3$-54 -5 3($-"0,+ 1%+&9'!R #-$*H(5-0 .6(-.-(&)+0* 1-G#C #,+)) .(0 4*)L-#T

    c(*%9"/3"%)-/II9 a+* $" >%'- 0-.%04(6%'R.( &.+#* '-&0%+%/61,+ 9,'68-.(,(6%'.R"(5+#-"(C H*.,(*## .(0 )*$/.13DTR"($1-G+$*# $" 0-',+ @6.-,.-

    _%5/3 [email protected]*(.) 5.-)+1*II EP !D*)"'. ,-0(*DF90+* $" 71"$*-(.&*"+#$+G+).1 &.#$#&"'4"#*0 "5 B*(&* i"(*# 41"$*-(C H/-&/ 0.'.3*# 1*(.) $+G+).1 &*))#T

    F%*+9,"/3"-5,[email protected] )%$/6$/$-" "/3"-X-"/$-,5"5 $/* $+G+).1 &*)) G.#*'*($ '*'G1.(*T71-'.1D .'D)"-0"#-#9)-3/$ &/.-(# &"(L*1$*0 -($" .'D)"-0 6 0*4"#-$*0 -( ,-0(*D_%"#99%5$ -5X%"$-,56

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    9/15

    E,3-$/9( *3/6)/"($,)/ 02abE19%6%5"% ,X Q 0(34&-+ 02 6*-.%1 Z-423=4 )%10431)> B7, ,#$",)%[email protected]

    E$/83% ",#96%

    >9,49%66-,5 $, QQTK#YW

    _%)%)8%9ii QFeH -) QAA 3: 13+38,3+', )[email protected]&

    '()*+,*3/6)/"($-" 3()*+,)/

    I "%33 $#),9 ",)*,6%C ,X0,')1'8%43-/ ,%10238%4&)$+/$ 6%"9%$% X*Q55

    S42 "/#6%6 / 2%0&(6-)83)-4% )%+/(31& .Z/

    f',/&+)4(31M) 1'8(3*,3

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    10/15

    c-6$-,"($,6-6 oZ'/54%9+/56 "%33 c-6$-,"($,6-69,45,[email protected] ('0-/,% :'4',

    S6 / 2/3-45/5$ +-6$-,"($,6-6=

    H""#96 -5 "+-3C9%5 N $, ] (%/96 ,X /4%

    S6 / )#3$-X,"/3 C-6,9C%9

    '%6-,56 *9%6%5$ -5 I,5%6D%5C,"9-5% 43/5C6 g %(%6=

    J3-5-"/3 [email protected]

    a%5%9/[email protected] X%?%9D 3,"/3-W%C 9/6+ ,5

    6"/3* /5C -5 %/9 "/5/36D

    ,$-$-6 )%C-/D )/6$,-C-$-6=

    J3/66-" $9-/C ,X [email protected] N%4-8 ,&)-3+-5 6.#33

    B-'

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    11/15

    >,3("($+%)-/ k%9/ G 2>K Q66%5$-/3 $+9,)8,"($+%)-/ G 2>K >9-)/9( 2(%3,X-89,6-6 G 2>K

    >1D$/1"-09 2%C-/5 /4% ,X "# %&'()

    : (*"4).#' .1-#-(3 51"' 9&+(64%(-'( 92-+%[email protected] .(-9&*))T

    J+/9/"$%9-W%C 8(@# 41"0+&$-"( "5 -02(50%[email protected]

    /0,'&+%12(61 J 9-/,B,02%12(61 -+-9-'(.:O(&1*.#*0'.11"H 41"0+&$-"( -# 1*5)*&$*0 -( 7B GD -02(50%12(%.6.

    E4")D&D$/*'-.FIIC 31.(+)"&D$"#-# .(0 $/1"'G"&D$"#-#T

    V"1 &)-(-&.) 5*.$+1*# 1*'*'G*1 X kKl

    c(*%9?-6",6-$(@ O(&1*.#*0 NBR '.##C 71*0-#4"#*# $"$/1"'G"$-& *4-#"0*# E'"#$ &"''"( &.+#* "5 0*.$/F

    -(&)+0-(3 !OC #$1",*C G"H*) -(5.1&$-"(C /*4.$-& L*-($/1"'G"#-# EB+00ZR/-.1- #D(01"'*F 1*$-(.) L*-(

    $/1"'G"#-#T

    c(*%9?,3%)-/@O(&1*.#* -( 4).#'. L")+'*2(-`+* $"

    7Ng .(0 (" "$/*1 &.+#* "5 4")D&D$/*'-.T

    c(*%9#9-"%)-/@# G1*.,0"H( "5 (+&)*.$*0 &*))# .(0-(&1*.#* -( 4+1-(* '*$.G")-#' E^ 3"+$F

    c-6$/)-5%)-/@ # 1*)*.#* "5 /-#$.'-(* 51"' G.#"4/-)#.(0 '.#$ &*))#T:##"& [email protected] L.#"0-).$.$-"(!4)*$/"1-&.44*.1-(3 5.&* .(0 *9#9-$-6E1*)*.#* 1*.&$-"( "5 '.#$

    &*))# .5$*1 H.1' G.$/F .(0 *%*$-" #3"%9 C-6%/6%51"'/-#$.'-(* #$-'+).$-"( "5 3.#$1-& .&-0T

    '/[email protected]#KR= bH

    >[email protected] 7.&,*0 H-$/ NBR#C 7).$*)*$#9# E=/1"'G"&D$"#-#FWBR9#E)*+,"&D$"#-# F#G.#"4/-)# .(0 *"#-("4/-)#[email protected] :)) /*'.$"4"-*$-& *)*'*($# -(&1*.#*0 E*Q&*4$

    )D'4/"&D$*#F c(*%9"%33#3/9 [email protected] 5-G1"#-# -( ).$*1 #$.3*#T=Q9 7/)*G"$"'D9 $1*.$'*($ "5 &/"-&*C =" 9%C#"% _IJ

    )/66C"V*!0*&1*.#*0 NBR 41"0+&$-"(7/)*G"$"'D m /D01"QD+1*.!:L3 #+1L-L.) AYZAn D*.1#

    2%4/./9(,"($%[email protected] ?*.#$ &"''"( $D4* "5

    !7aT

    >/$+,4%5%[email protected]%,*3/6$-" 6$%) "%33

    C-6,9C%9 7-$+ *9,3-X%9/$-,5 ,X1&*'@'(%38%4&) P,'4&,&4) '(& -+8(&')&/O

    +,7%?%9 $+%( /9% 5,5X#5"$-,5/3= _IJ6

    /5C 49/5#3,"($%6 /36, -5"9%/6%C

    R/.1.&$*1-U*0 GD#4).$*)*$ &"+($E&"''"()D 31*.$*1 $/.( [email protected]?F -(7BT B)**0-(3 0+* $" +.)-$.$-L* 4).$*)*$0*5*&$ 2#+.))D 8O G)**0#

    =/1"'G"#-#9 a+* $"#(+'G*1#ag=C 4"1$.) .(0 /*4.$-& L*-( $/1"'G"#-#C

    !O .(0 =O:

    S4)*("'*3.)D>1D$/1"'*).)3-.9 $/1"GG-(3 .(0 G+1(-(3 "5

    +/5C6 /5C X%%$0+* $" G)""0 L*##*)"&&)+#-"(=

    c/5C6 /5C P%%$

    P-89,83/6$KaP

    B"$/ #$-'+).$* '.11"H 5-G1"#-#T _IJV6 /9% C%X,9)%CGD5-G1"+# $-##+* H/*( *($*1-(3 $/* #-(+#"-0# /*(&* 41"0+&-(3

    &).##-& $%/9C9,* /**%/9/5"%=

    b5",)),5-( 4.$-*($# #5C%9 `L (%/96 ,X /4%=2/66-?% 6*3%5,)%4/3(@#*&"(0.1D $" %f$9/)%C#33/9(

    +%)/$,*,-%6-6!S4)*(-& -(5.1&$#T>[email protected] '%#.,%9($+9,83/6$-" 6)%/9 B7, )/q,9 ,#$",)%[email protected]

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    12/15

    K-XX%9%5$-/3 C-/45,6-6 ,X *,3("($+%)-/

    >,3("($+%)-/ )%/[email protected]"9%/6%C _IJ ",#5$D c8 /5C c%)/$,"9-$

    _IJ ",#5$ ?%96#6 _IJ )/[email protected]

    _IJ ",#5$ -6 $+% 5#)8%9 ,X _IJ *%9 #' ,X 83,,C

    _IJ )/66 -6 $+% $,$/3 5#)8%9 ,X _IJ6 -5 $+% 8,C( -5 )3Z.4

    _%3/$-?% *,3("($+%)-/9K#% $, 3,66 -5 *3/6)/ ?,3#)%

    AT

    #_IJ ",#5$< C#% $, /" -5 *3/6)/ ?,3#)% 9 Qf/)*3%@ ?,3#)% C%*3%$-,5 X9,) 67%/$-54cT

    _IJ )/66 -6 5,9)/3H /5C E/,N /9% 5,9)/3 !86,3#$% *,3("($+%)-/ 9_%X3%"$6 rr _IJ *9,C#"$-,5 8( I2

    I,$+ "+/9/"$%9-W%C 8(@#< -5 I2 *9,C#"$-,5 ,X _IJ6 C#< _IJ ",#5$ /5C _IJ )/66 !**9,*9-/$% /86,3#$% *,3("($+%)-/9 >,3("($+%)-/ C#% $, +(*,f-/ S5/**9,*9-/$% /86,3#$% *,3("($+%)-/9>,3("($+%)-/ -5 /86%5"% ,X +(*,f-/

    SX $+%9% -6 / +(*,f-" 6$-)#3#6 X,9 Q>H 9%3%/6% Qf/)*3%@ *9-)/9( 3#54 C-6%/6%D "(/5,$-" ",54%5-$/3 +%/9$ C-6%/6%D 3-?-54 /$

    +-4+ /3$-$#C%

    "< HN 6/$#9/$-,5C#< _IJ ",#5$D _IJ )/66D Q>HF,9)/3< >3/6)/ ?,3#)% 0>k1

    X: 42&(& -) +3 2%03S-8 )4-1=,=) :3( RPa (&,&')&

    >,3("($+%)-/ 9#89/ ?%9/

    #< _IJ ",#5$D _IJ )/66D >k "< Q>HD F,9)/3 E/,N

    Q"$,*-" 6%"9%$-,5 ,X Q>H 0_%5/3 "%33 "/9"-5,)/1

    #< _IJ ",#5$D _IJ )/66D Q>H F,9)/3< >k /5C E/,N

    K"'*1ZW1-3/$ N"#*$$*#P\*+1"G).#$"'.

    P>H-(3 S.1&"'.

    P!*0+))"G).#$"'.

    PN*$-("G).#$"'.

    K-XX%9%5$-/3 C-/45,[email protected] H$+%9 6)/33 9,#5C 83#% "%33 $#),96

    2%$/6$/$-" 5%#9,83/6$,)/

    2%$/6$/$-" )/3-45/5$ 3()*+,)/

    !"#$% 3()*+,83/6$-" 3%#.%)-/

    _+/8C,)(6/9",)/

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    13/15

    B+9,)8,"($,*%5-/@ "*9,C#"$-,5!66,"-/$%C 7-$+ K%"9%/6%C

    2%4/./9(,"($%6 -5 I2

    K#% $, 4%5%9/3-W%C C-6%/6%6 ,X I2

    AT !*3/6$-" /5%)-/

    cT I,5% )/99,7 -5X-3$9/$-,5 02(%3,*+$+-6-61

    G '%#.%)-/C 2%$/6$/$-" "/9"-5,)/C 2(%3,X-89,6-6 _T k-$/)-5 I:NZX,3/$% C%X-"-%5"(

    G S5%XX%"$-?% +%)/$,*,-%6-6D >/5"($,*%5-/

    XT

    J+%),$+%9/*%#$-" /4%[email protected] I2 6#**9%66-,5

    B+9,)8,"($,*%5-/ "6#9?-?/3 0# C%6$9#"$-,51

    SC-,*/$+-" B+9,)8,"($,*%5-">#9*#9/

    0SB>1

    :+$"-''+(* 0-#*.#* -( H/-&/ G"0D 41"0+&*# .($-G"0-*# .3.-(#$ 4).$*)*$#T=/*#* !5$-*3/$%3%$ /5$-8,C-%6 0S4a10-1*&$*0 .3.-(#$ 4).$*)*$ '*'G1.(* 43(",*9,$%-56 6#"+ /6 F0 XX3/$%3%$ ",#5$#I3%%C-54 B-)%

    >%9-*+%9/3 6)%/[email protected]+9,)8,"($,*%5-/

    [email protected] #-5 5#)8%9 ,X )%4/./9(,"($%6 7-$+ -))/$#9% X,9)6=

    !"#$% SB> Q*-C%)-,3,4(@ M&&+1# '"#$ "5$*( -( &/-)01*( EcZn D1#F M5$*( 5"))"H# . L-1.) -(5*&$-"( Eb_BSF

    [email protected] V"))"H-(3 . G"+$ "5 2N=O 4.$-*($# 0*L*)"49 :G1+4$ "(#*$ "5 *.#D G1+-#-(3C 4*$*&/-.*C *4-#$.Q-# .(0 G)**0-(3 51"' '+&"+

    '*'G1.(*#T S*)5Z)-'-$*0 0-#"10*1C f Q*-C%)-,3,4(@ !"1* &"''"( -( .0+)$#@D"+(3 H"'*( EcYZXY D1#FT 2#+.))D .##"&-.$*0 H-$/ S?>IIIT O$ '.D G* $/* 860.(

    '.(-5*#$.$-"([email protected] 81.0+.) -( "(#*$ .(0 &/.1.&$*1-U*0 GD 4*$*&/-.*C *.#D G1+-#.G-)-$DC *4-#$.Q-#C 3+' G)**0-(3 .(0 /*'"11/.3*# .5$*1 '-("

    $1.+'.T S4)*("'*3.)D +#+.))D 41*#*($ +()-,* -( &/-)01*(

    >/$+,4%5%[email protected] R.+#*0 GD 5"1'.$-"( "5 .+$".($-G"0-*# EO38F .3.-(#$ 4).$*)*$ '*'G1.(* 3)D&"41"$*-(# EOOGZOOO.FT M4#"(-U*0

    4).$*)*$# 1*'"L*0 GD #4)*(-& '.&1"4/.3*#T

    B9%/$)%[email protected] J,9$-",6$%9,-C6D 6*3%5%"$,)(D !3.(3/$-54 /4%5$6D Sk 4/))/ 43,8#3-56-5 G)**0-(3 &.( ("$ G* &"($1"))*0

    B+9,)8,"($,*%5-/@ # ",56#)*$-,5J,)),5 X%/$#9%[email protected]>Q$*(#-L* 5"1'.$-"( "5 )-"9,$+9,)8-$/1"+3/"+$ $/* L.#&+).$+1*T =/-# &"(#+'*# 4).$*)*$#D 3%/C-54 $, $+9,)8,"($,*%5-/

    :)) *Q/-G-$ )-"9,/54-,*/$+-" +%),3($-" /5%)-/ 02!c!1*L-0*(&*0 GDE"+-6$,"($%6"( 4*1-4/*1.) G)""0 #'*.1

    B+9,)8,$-" $+9,)8,"($,*%5-" *#9*#9/

    0BB>1

    Q$-,3,4(Z>/$+,4%5%[email protected] a*5-&-*(&D "5 ?^P "3%/?-54 %5W()% .Z/ !K!2BEG:UT >Q&*## "5 LWV -(&1*.#* .0/*#-"( "5

    4).$*)*$# $" *(0"$/*)-+'T =/-# &.+#*# X,9)/$-,5 ,X )-"9,$+9,)8-)*.0-(3 $" $/1"'G"&D$"4*(-. E&"(#+'4$-"( "5

    4).$*)*$#FT 2#+.))D #**( -( H"'*(

    J3/66-" *%5$/C "5 #-3(# .(0 #D'4$"'#9 V*L*1C =/1"'G"&D$"4*(-.C N*(.) 5.-)+1*C !-&1".(3-"4.$/-& /*'")D$-& .(*'-.H-$/ #&/-#$"&D$*#C :)$*1*0 '*($.) #$.$+# ER\S 0*5-&-$#FT J3-5-"/3 */$+,3,4(@V.$.) -5 ("$ $1*.$*0 =1*.$'*($ -# *3/6)/ %f"+/54%C H/-&/ 1*4).&*# :a:!=SZA_T =1*.$*0 H-$/

    #$*1"-0#T

    '/[email protected] >3/$%3%$ ",#5$ /5C#

    IBC \"1'.) 7= .(0 .7==

    >%9-*+%9/3 6)%/[email protected] $/1"'G"&D$"4*(-. .(0 #&/-#$"&D$*# .(0 1*$-&+)"&D$"#-#T

    c%),3($-" #9%)-" 6(5C9,)% 0cbE1 Q$-,3,4( /5C */$+,4%5%[email protected]+#*0 GD #*4#-#C *#4*&-.))D H-$/ Q=",3- H:][email protected]&$*1-.) $"Q-(# E*#4*&-.))D > &")- #/-3.Z

    )-,* $"Q-(F &.+#* >(0"$/*)-.) 0.'.3*T =/-# )*.0# $" 5"1'.$-"( "5 4).$*)*$ '-&1"$/1"'G- .(0 $/1"'G"&D$"4*(-.T

    M13.(-#'# 41")-5*1.$* -( +(0*1&"",*0 G**5 EK.'G+13*1#F J3-5-"/3 */$+,3,4(@!"#$ &"''"()D #**( -( &/-)01*( 5"))"H-(3 3.#$1"*($*1-$-# EH-$/ G)""0D 0-.11/*.IFT S-3(# .(0

    #D'4$"'# .1* #-'-).1 $" ==7 *Q&*4$9 N*(.) 5.-)+1* -# '"1* &"''"( .(0 '"1* #*L*1*T R\S #D'4$"'# .1* )*## &"''"(T

    '/[email protected] *3/$%3%$ ",#5$.(0# IB\"1'.) 7= .(0 .7==>[email protected] $/1"'G"&D$"4*(-. .(0 #&/-#$"&D$*# .(0 1*$-&+)"&D$"#-#T

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    14/15

    K-66%)-5/$%C -5$9/?/6"#3/9 ",/4#3/$-,5

    0KSJ1

    : $/1"'G"Z/*'"11/.3-& 0-#"10*1 W-0*#41*.0 &)"$$-(3 H-$/ 1*#+)$.($ &"(#+'4$-"( "5 4).$*)*$# .(0 &".3+).$-"( 5.&$"1#

    E%6*= X/"$,96 kD kSSS /5C X-89-5,4%5F P 83+)=104-3+ 83'*=,30'42%>: $/1"'G"$-& 4/*("'*("( .(0 /*'"11/.3*T

    KSJ ?-/ N )%"+/5-6)69 N*)*.#* "5 $-##+* 5.&$"[email protected] $/1"'G"4).#$-& #+G#$.(&* -( &-1&+).$-"(T O(p+1D $" *(0"$/*)-.) &*))#T

    Q$-,3,4(@E%*6-6q*(0"$"Q-& #/"&, E!RRFr >#4*&-.))D Q=",3- /5C F=)%5-54-$-C-6D !.)-3(.(&D9 *#4*&-.))D &"''"( -( Z!2' 2UE.&+$* 41"'D*)"&D$-& )*+,*'-.FC >/5"9%/$-" "/5"%9CMG#$*$1-&.) &"'4)-&.$-"(#9 >3/"%5$/ *9%?-/C /)5-,$-"

    X3#-C %)8,3-6)C 9%$/-5%C C%/C X%$#6C B9/#)/ s *#4*&-.))D &1+#/ -(p+1-*#

    >/$+,4%5%[email protected]*#41*.0 .&$-L.$-"( "5 &".3+).$-"( #D#$*' 0+* $" %f*,6#9% $, $-66#% $+9,)8,*3/6$-5.(0 "1%5C,$+%3-/3 "%33 -5q#9(=?*.0# $" *Q$*(#-L* $/1"'G+# 5"1'.$-"( -( '-&1"L.#&+).$+1*C 1*#+)$-(3 -( ,86$9#"$-,5 ,X 83,,C

    X3,79 &.+#*# $-66#% +(*,f-/ /5C C/)/4%T R"(#+'4$-"( "5 &)"$$-(3 5.&$"1# .(0 4).$*)*$#9 &.+#*# G)**0-(3T !"$-?/$-,5 ,X-89-5,3($-" 6(6$%) 8( X/"$,9 oSS/ "/#6%6 *9,C#"$-,5 ,X PK>6 /5C KGC-)%96=

    I3%%[email protected] M&&+)$ "1 V1.(,C 4*$*&/-.*C 4+14+1.C '+&"#.) G)**0-(3 *$&T

    J3,[email protected]!OC 7>C ag=C .01*(.) -(5.1&$-"(C 2-"9,/54-,*/$+-" +%),3($-" /5%)-/C N*#4-1.$"1D #D'4$"'#J aD#4(*.C

    1*#4-1.$"1D 0-55-&+)$DC \*+1")"3-&.) #-3( .(0 #D'4$"'#C M)-3+1-. .(0 .&+$* 1*(.) 5.-)+1*T M13.( 0D#5+(&$-"( .(0 5.-)+1*

    2,9*+,3,4(@!-&1"$/1"'G- EV-G1-( .(0 4).$*)*$#F [email protected] -(5.1&$-"(#@/*'"11/.3*# -( "13.(# E,-0(*D#C )+(3#C G1.-(C

    .01*(.)#FJ,/4#3/$-,5 $%[email protected]>9,3,54%C >B /5C >BBC K%"9%/6%C X-89-5,4%5D P/"$,9 k /5C P/"$,9 kSSS

    >3/$%3%$ $%6$69 B+9,)8,"($,*%5-/D *9,3,54%C IB

    P-89-5,3(6-6 $%[email protected]>9%6%5"% ,X PK>6 /5C K C-)%96

  • 8/11/2019 Acute Lymphocytic Leukemia TABLE

    15/15

    c%9%C-$/9(@ K-6,9C%96 ,X *3/$%3%$ !aa_Qa!BSHF

    a3/5W)/55 $+9,)8/6$+%5-/ K*1*0-$.1D 0*5-&-*(&D "5 a*SS8SSS/ X-89-5,4%5 9%"%*$,9E1*`+-1*0 5"1 5"1'.$-"( "5 5-G1-("3*( G1-03*#

    G*$H**( .0p.&*($ 4).$*)*$#FJ R.+#*# 0*5*&$ -( 4).$*)*$ .331*3.$-"( s 4).$*)*$# &.(u$ G-(0 5-G1-("3*(T

    ?-5*)"(3 G)**0-(3 41"G)*'#B=!6*-9-5ZFE!SK6

    7).$*)*$ .331*3.$-"( 0*5*&$T O(/-G-$-"( "5 4).$*)*$ &D&)"Z

    "QD3*(.#*C H/-&/ +)$-'.$*)D -5+-8-$6 6(5$+%6-6 ,X Bo!N

    E4).$*)*$ .33FT \"1' 4).$*)*$ &"+($T# B=

    _%5/3 X/-3#9%Z#9%)-/!85,9)/3 83%%C-54-# &"''"( -( _P"1 #9%)-/

    S5+-8-$-,5 ,X *3/$%3%$ *+,6*+,3-*-CGD $,f-" *9,C#"$6&.+#-(3 /449%4/$-,5 C%X%"$